SCHEMBL15936181

SCHEMBL15936181

COc1cc(F)cc(I)c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.46
NQO2 P16083 1/20 0.39
TAAR1 Q96RJ0 1/20 0.38
CYP1A1 P04798 1/20 0.36
CYP1B1 Q16678 1/20 0.36
CYP3A4 P08684 1/20 0.34
NFE2L2 Q16236 4/20 0.34
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA7 P43166 1/20 0.33
CA9 Q16790 1/20 0.33
CA14 Q9ULX7 1/20 0.33
KDM1A O60341 1/20 0.33
FFAR4 Q5NUL3 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
RELA Q04206 1/20 0.32
APP P05067 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30074410 1.00 ALDH1A1 (0.46) ALDH1A1NQO2TAAR1CYP1A1CYP1B1
SCHEMBL388181 0.82 ALDH1A1 (0.69) ALDH1A1NQO2CYP1A1CYP1B1CYP3A4
SCHEMBL168353 0.82 ALDH1A1 (0.69) ALDH1A1NQO2TAAR1CYP1A1CYP1B1
SCHEMBL186502 0.82 ALDH1A1 (0.59) ALDH1A1NQO2TAAR1CYP1A1CYP1B1
SCHEMBL811852 0.82 ALDH1A1 (0.59) ALDH1A1NQO2CYP1A1CYP1B1CYP3A4
SCHEMBL2227610 0.76 KAT6A (0.35) ALDH1A1FFAR4NPC1RAB9ARELA
SCHEMBL21577485 0.76
SCHEMBL2225192 0.76 FGFR1 (0.41) CYP3A4NPC1APP
SCHEMBL11885 0.73 ALDH1A1 (0.48) ALDH1A1NQO2TAAR1CYP1A1CYP1B1
SCHEMBL388119 0.73 ALDH1A1 (0.48) ALDH1A1CYP1A1CYP1B1CYP3A4CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240246969-A1 HETEROCYCLIC DERIVATIVES AS CAMKK2 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2024-07-25 US disclosed
EP-4337660-A1 HETEROCYCLIC DERIVATIVES AS CAMKK2 INHIBITORS Bristol-Myers Squibb Company (US) 2024-03-20 EP disclosed
CN-117597345-A Heterocyclic derivatives as CaMKK2 inhibitors 百时美施贵宝公司 2024-02-23 CN disclosed
US-20220017499-A1 Process for Preparing 1-([3R,4S)-4-Cyanotetrahydropyran-3-YL]-3-[(2-fluoro-6-Methoxy-4-Pyridyl)Amino]Pyrazole-4-Carboxamide INTERVET INC. (US) 2022-01-20 US disclosed
EP-3223822-B1 BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS ENANTA PHARM INC (US) 2020-07-01 EP disclosed
EP-2516445-B1 TRICYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS CEPHALON INC (US) 2015-03-11 EP disclosed
EP-2792678-A1 Tricyclic derivatives and their pharmaceutical use and compositions CEPHALON, INC. (US) 2014-10-22 EP disclosed
EP-2516446-B1 SUBSTITUTED HEXAHYDROCHROMENO[3,4-B]PYRROLES WITH AFFINITY FOR THE SEROTONIN RECEPTOR (5-HT) FAMILY CEPHALON INC (US) 2014-08-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240246969-A1 HETEROCYCLIC DERIVATIVES AS CAMKK2 INHIBITORS CAMKK2, CAMKK1, CAMK1 ALDH1A1 3614/4885NQO2 2672/4885TAAR1 4087/4885
US-20220017499-A1 Process for Preparing 1-([3R,4S)-4-Cyanotetrahydropyran-3-YL]-3-[(2-fluoro-6-Methoxy-4-Pyridyl)Amino]Pyrazole-4-Carboxamide CYP4B1, CYP3A4, CYP4F3 ALDH1A1 473/4885NQO2 690/4885TAAR1 867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.